Turpeenniemi-Hujanen T - Search Results

1

8-hydroxydeguanosine and nitrotyrosine are prognostic factors in urinary bladder carcinoma.

Soini Y, Haapasaari KM, Vaarala MH, Turpeenniemi-Hujanen T, Kärjä V, Karihtala P. Soini Y, et al. Int J Clin Exp Pathol. 2011 Mar;4(3):267-75. Epub 2011 Mar 2. Int J Clin Exp Pathol. 2011. PMID: 21487522 Free PMC article.

2

p53 protein expression is correlated with benzo[a]pyrene-DNA adducts in carcinoma cell lines.

Rämet M, Castrén K, Järvinen K, Pekkala K, Turpeenniemi-Hujanen T, Soini Y, Pääkkö P, Vähäkangas K. Rämet M, et al. Carcinogenesis. 1995 Sep;16(9):2117-24. doi: 10.1093/carcin/16.9.2117. Carcinogenesis. 1995. PMID: 7554063

3

Proliferating cell nuclear antigen but not p53 or human papillomavirus DNA correlates with advanced clinical stage in renal cell carcinoma.

Kamel D, Turpeenniemi-Hujanen T, Vähäkangas K, Pääkkö P, Soini Y. Kamel D, et al. Histopathology. 1994 Oct;25(4):339-47. doi: 10.1111/j.1365-2559.1994.tb01352.x. Histopathology. 1994. PMID: 7835839

4

p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression.

Soini Y, Turpeenniemi-Hujanen T, Kamel D, Autio-Harmainen H, Risteli J, Risteli L, Nuorva K, Pääkkö P, Vähäkangas K. Soini Y, et al. Br J Cancer. 1993 Nov;68(5):1029-35. doi: 10.1038/bjc.1993.475. Br J Cancer. 1993. PMID: 8217593 Free PMC article.

5

Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma.

Kuittinen O, Soini Y, Turpeenniemi-Hujanen T. Kuittinen O, et al. Eur J Haematol. 2002 Oct;69(4):205-12. doi: 10.1034/j.1600-0609.2002.02751.x. Eur J Haematol. 2002. PMID: 12431239

6

Clinicopathological correlations of TIMP-1 and TIMP-2 in Hodgkin's lymphoma.

Pennanen H, Kuittinen O, Soini Y, Turpeenniemi-Hujanen T. Pennanen H, et al. Eur J Haematol. 2004 Jan;72(1):1-9. doi: 10.1046/j.0902-4441.2004.00168.x. Eur J Haematol. 2004. PMID: 14962256

7

Changing prognostic role of preserved dendritic cell reticulum in Hodgkin's lymphoma.

Outi K, Järvinen M, Soini Y, Weber E, Turpeenniemi-Hujanen T, Blanco G. Outi K, et al. Leuk Lymphoma. 2004 May;45(5):1081-2. doi: 10.1080/104281904310001641206. Leuk Lymphoma. 2004. PMID: 15291373 No abstract available.

8

Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors.

Määttä M, Santala M, Soini Y, Talvensaari-Mattila A, Turpeenniemi-Hujanen T. Määttä M, et al. Tumour Biol. 2004 Jul-Aug;25(4):188-92. doi: 10.1159/000081101. Tumour Biol. 2004. PMID: 15557756

9

Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.

Hoikkala S, Pääkkö P, Soini Y, Mäkitaro R, Kinnula V, Turpeenniemi-Hujanen T. Hoikkala S, et al. Cancer Lett. 2006 May 8;236(1):125-32. doi: 10.1016/j.canlet.2005.05.012. Epub 2005 Jun 27. Cancer Lett. 2006. PMID: 15982804

10

Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma.

Talvensaari-Mattila A, Santala M, Soini Y, Turpeenniemi-Hujanen T. Talvensaari-Mattila A, et al. Anticancer Res. 2005 Nov-Dec;25(6B):4101-5. Anticancer Res. 2005. PMID: 16309203 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

162 results

Search Page

Filters